Edwards Lifesciences Corporation (EW)
Automate Your Wheel Strategy on EW
With Tiblio's Option Bot, you can configure your own wheel strategy including EW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EW
- Rev/Share 10.4542
- Book/Share 17.5827
- PB 4.6887
- Debt/Equity 0.0686
- CurrentRatio 4.0043
- ROIC 0.1148
- MktCap 48400527380.0
- FreeCF/Share 1.3856
- PFCF 60.1847
- PE 44.7137
- Debt/Assets 0.0528
- DivYield 0
- ROE 0.1047
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | EW | TD Cowen | Hold | Buy | -- | $97 | Jan. 9, 2026 |
| Upgrade | EW | JP Morgan | Neutral | Overweight | -- | $100 | Dec. 18, 2025 |
| Upgrade | EW | Raymond James | Market Perform | Outperform | -- | $96 | Nov. 3, 2025 |
| Upgrade | EW | Wolfe Research | Underperform | Peer Perform | -- | -- | Oct. 29, 2025 |
| Upgrade | EW | Jefferies | Hold | Buy | -- | $98 | Oct. 29, 2025 |
| Downgrade | EW | Oppenheimer | Outperform | Perform | -- | -- | Oct. 8, 2025 |
| Upgrade | EW | Evercore ISI | In-line | Outperform | -- | $88 | Oct. 7, 2025 |
| Upgrade | EW | BTIG Research | Neutral | Buy | -- | $100 | July 29, 2025 |
| Upgrade | EW | Piper Sandler | Neutral | Overweight | -- | $80 | April 24, 2025 |
| Upgrade | EW | Stifel | Hold | Buy | $75 | $90 | Jan. 30, 2025 |
News
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
Published: February 12, 2026 by: MarketBeat
Sentiment: Positive
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.
Read More
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights
Published: February 12, 2026 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Read More
EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Positive
Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.
Read More
Ahead of Edwards Lifesciences (EW) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
EW gears up for Q4 earnings as investors watch TAVR momentum, fast-growing TMTT sales and steady surgical heart demand.
Read More
Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Li.
Read More
EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.
Read More
4 Large-Cap MedTech Stocks to Keep Winning Streaks Alive in 2026
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Four large-cap MedTech leaders, MDT, ISRG, CAH, EW, appear well-positioned to extend their winning streaks in 2026 on resilient procedure demand and innovation.
Read More
Should You Continue to Hold EW Stock in Your Portfolio?
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
Read More
BSX vs. EW: Which Heart Device Stock Is the Smarter Investment Now?
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.
Read More
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Read More
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
Read More
Exploring Analyst Estimates for Edwards Lifesciences (EW) Q3 Earnings, Beyond Revenue and EPS
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
Successful Patient Outcomes Demonstrated With Edwards' SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025
Published: October 27, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement.
Read More
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
Published: October 27, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards' leadership in setting the standard for lasting valve performance and excellent patien.
Read More
EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
Published: October 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).
Read More
Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates.
Read More
Edwards Lifesciences: Inflection Incoming, But When?
Published: October 14, 2025 by: Seeking Alpha
Sentiment: Positive
Edwards Lifesciences Corporation remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and consistent revenue growth. EW's TMTT segment is the fastest-growing area, but margin pressures, stagnating EPS, and declining returns limit near-term upside potential. Despite a robust balance sheet and ongoing share buybacks, EW's valuation appears stretched relative to its growth and industry peers.
Read More
EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).
Read More
3 Healthcare Pathbreakers With Long-Term Tailwinds
Published: September 01, 2025 by: MarketBeat
Sentiment: Positive
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and never achieve them.
Read More
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, according to Grand View Research. Abbott Laboratories ABT and Edwards Lifesciences EW are two key players with significant presence in this sector.
Read More
Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care
Published: August 29, 2025 by: Business Wire
Sentiment: Neutral
MADRID--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis (AS) patients, regardless of symptoms. The guidelines enable a proactive approach to disease management and underscore that intervention should be considered for asymptomatic patients, regardless of heart function, which is a meaningful step forward from the prior practice of “watchful waiting.” Th.
Read More
JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition by Edwards Lifesciences.
Read More
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve
Published: August 06, 2025 by: Reuters
Sentiment: Negative
The U.S. Federal Trade Commission sued to block Edwards Lifesciences Corp's acquisition of JenaValve Technology Inc, saying in a lawsuit filed in Washington on Wednesday the merger would decrease competition in the market for a device meant to treat a potentially fatal heart condition.
Read More
Edwards Lifesciences Comments on FTC's Action to Block Proposed Acquisition of JenaValve
Published: August 06, 2025 by: Business Wire
Sentiment: Neutral
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology. Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of.
Read More
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027
Published: August 06, 2025 by: Benzinga
Sentiment: Neutral
Edwards Lifesciences EW has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock's setup doesn't necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027.
Read More
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Read More
Curious about Edwards Lifesciences (EW) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Read More
Should You Add Edwards Lifesciences Stock to Your Portfolio Now?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative
EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.
Read More
Smart Money Going in Senior Health: Key Stocks in Elderly Care
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Read More
About Edwards Lifesciences Corporation (EW)
- IPO Date 2000-03-27
- Website https://www.edwards.com
- Industry Medical - Devices
- CEO Bernard J. Zovighian
- Employees 15800